Abstract
Background The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial assessed dapagliflozin versus placebo, in a......
小提示:本篇文献需要登录阅读全文,点击跳转登录